Why the study?
Does OKY-046 reduce ischemia-induced ventricular arrhythmias in anesthetized dogs undergoing coronary artery ligation and reperfusion?
Does OKY-046 reduce ischemia-induced ventricular arrhythmias in anesthetized dogs undergoing coronary artery ligation and reperfusion?
Inhibition of thromboxane synthesis with OKY-046 significantly decreases ischemia-induced ventricular arrhythmias in a canine model.
Answers are grounded in this paper and cite their sources.
No change to clinical care; leaves open whether thromboxane inhibition prevents ventricular arrhythmias in human ischemia-reperfusion.
Effects of OKY-046, a selective thromboxane synthetase inhibitor, on ischemia-induced ventricular arrhythmias were investigated in anesthetized dogs. OKY-046 (30 mg/kg, intravenously) decreased ventricular arrhythmias significantly both during 30 min of coronary artery ligation and subsequent reperfusion, which corresponded with a significant reduction of thromboxane concentration, suggesting that thromboxane released during ligation is an important factor in the development of ventricular arrhythmias. Inhibition of thromboxane synthesis with OKY-046 might be useful for the prevention of ischemia-induced ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Ogura et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: